Sign In
Buy XGN
$4.54
-0.280 (-5.81%)
At Close: Jun 03, 2026
Exagen to Announce Fourth Quarter 2023 and Full-Year Financial Results on March 18, 2024
04:05pm, Thursday, 07'th Mar 2024
CARLSBAD, Calif., March 07, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, will release financial results for the quarter and year ended December 31, 202
Despite Fast-paced Momentum, Exagen Inc. (XGN) Is Still a Bargain Stock
09:51am, Tuesday, 06'th Feb 2024
Exagen Inc. (XGN) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks that
Exagen Inc. Announces Select Preliminary Full-Year 2023 Results and Reaffirms Guidance
12:00pm, Sunday, 07'th Jan 2024
CARLSBAD, Calif., Jan. 07, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announces select preliminary unaudited financial results for th
Exagen Inc. (XGN) Q3 2023 Earnings Call Transcript
08:37am, Monday, 20'th Nov 2023
Exagen Inc. (NASDAQ:XGN ) Q3 2023 Earnings Conference Call November 13, 2023 4:30 PM ET Company Participants Ryan Douglas - IR John Aballi - President and CEO Kamal Adawi - CFO Conference Call Partici
Exagen Inc. Reports Strong Third Quarter 2023 Results
04:05pm, Monday, 13'th Nov 2023
SAN DIEGO, California, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended September
Exagen Inc. and Johns Hopkins University Announce License Agreement for Novel Patented Lupus Nephritis Biomarkers
04:05pm, Thursday, 09'th Nov 2023
SAN DIEGO, California, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, and Johns Hopkins University jointly announced today the execu
Exagen to Announce Third Quarter 2023 Financial Results on November 13, 2023
04:05pm, Monday, 30'th Oct 2023
SAN DIEGO, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, will release financial results for the quarter ended September 30, 2023, a
Exagen Announces Acceptance of Multiple Abstracts at ACR 2023 Annual Meeting
04:05pm, Thursday, 28'th Sep 2023
SAN DIEGO, California, Sept. 28, 2023 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, announced today the acceptance of five abstracts at the 2023
Exagen Inc. to Participate in the 2023 Cantor Fitzgerald Global Healthcare Conference
04:05pm, Tuesday, 12'th Sep 2023
SAN DIEGO, California, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced its participation in the 2023 Cantor Fitzgera
Exagen Inc. (XGN) Q2 2023 Earnings Call Transcript
01:42pm, Monday, 07'th Aug 2023
Start Time: 08:30 January 1, 0000 9:21 AM ET Exagen Inc. (NASDAQ:XGN ) Q2 2023 Earnings Conference Call August 07, 2023, 08:30 AM ET Company Participants John Aballi - President and CEO Kamal Adawi -
Exagen Inc. (XGN) Reports Q2 Loss, Tops Revenue Estimates
10:38am, Monday, 07'th Aug 2023
Exagen Inc. (XGN) came out with a quarterly loss of $0.28 per share versus the Zacks Consensus Estimate of a loss of $0.48. This compares to loss of $0.78 per share a year ago.
Exagen to Announce Second Quarter 2023 Financial Results on August 7, 2023
04:05pm, Tuesday, 25'th Jul 2023
SAN DIEGO, July 25, 2023 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, will release financial results for the quarter ended June 30, 2023, before
Exagen Inc. (XGN) Q1 2023 Earnings Call Transcript
10:23pm, Monday, 15'th May 2023
Exagen Inc. (NASDAQ:XGN ) Q1 2023 Earnings Conference Call May 15, 2023 4:30 AM ET Company Participants Ryan Douglas - Investor Relations John Aballi - President & Chief Executive Officer Kamal Adawi
Exagen Inc. (XGN) Reports Q1 Loss, Tops Revenue Estimates
06:59pm, Monday, 15'th May 2023
Exagen Inc. (XGN) came out with a quarterly loss of $0.44 per share versus the Zacks Consensus Estimate of a loss of $0.52. This compares to loss of $0.60 per share a year ago.
XGN Stock: 14.89% Drop After Hours Explanation
11:32pm, Monday, 20'th Mar 2023
The stock price of Exagen Inc (NASDAQ: XGN) fell by 14.89% after hours in the most recent trading session. This is why.
